“We are at an exciting time in the care of patients with cancer. We continue to have newer, better treatments – advancing our knowledge, enabling us to target these therapies more to each individual. At VCS you can be assured that you will receive state-of-the-art cancer care that is the best plan for you and your family.”
Work and Credentials:
Primary Location
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology and Internal Medicine
Fellowship
University of North Carolina Hospitals, Medical Oncology and Hematology
Residency
Rutgers Robert Wood Johnson Medical School
Medical School
Rutgers Robert Wood Johnson Medical School
College
Rutgers University
Special Interests
Thoracic, Gastrointestinal (Colorectal, hepatobiliary, gastric)
Dr. Timothy A. McCarthy graduated with high honors from Rutgers University where he received a Bachelor of Science in Materials Engineering. He then went on to earn his medical degree and complete an Internal Medicine residency at Rutgers Robert Wood Johnson Medical School. During his residency, Dr. McCarthy was honored with the Nilesh Tamakuwala, MD Memorial Award, a distinction presented to the individual who best demonstrated compassion in care and excellence in teaching.
Board-certified in Medical Oncology, Hematology and Internal Medicine, Dr. McCarthy completed his fellowship in Medical Oncology and Hematology at University of North Carolina Hospitals. As an Oncology Fellow, Dr. McCarthy took a leadership role working with various departments with a specific interest in quality and process improvement projects. Dr. McCarthy is a published author and has presented posters at various medical events, including the annual American Society of Clinical Oncology (ASCO) symposium.
Outside of medicine, Dr. McCarthy enjoys staying active and exploring the outdoors with his wife and 3 young children. He also enjoys listening to a diverse array of music and plays several different instruments.
Physician Video:
'
Physician Publications
January 1, 2016
Importance of pharmacokinetic studies in the management of acquired factor X deficiency
Read MoreClinical Trials (3)
Clinical Trial 21318
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Clinical Trial 20423
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Clinical Trial 8951-CL-0103
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
